| Stereochemistry | EPIMERIC |
| Molecular Formula | C15H14O7 |
| Molecular Weight | 306.2675 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1C(O)C2=C(O)C=C(O)C=C2O[C@@H]1C3=CC=C(O)C(O)=C3
InChI
InChIKey=SBZWTSHAFILOTE-NOYMGPGASA-N
InChI=1S/C15H14O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,13-21H/t13?,14-,15+/m0/s1
| Molecular Formula | C15H14O7 |
| Molecular Weight | 306.2675 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Leucocianidol is a vasoprotector. It increases the resistance of vessels and decreases their permeability. Leucocianidol increases the tonicity of the veins. Leucocianidol is used in the management of capillary fragility, hemorrhoids, venolymphatic insufficiency. In combination with lidocaine and hydrocortisone, it is used in the symptomatic treatment of hemorrhoidal crisis. Leucocianidol inhibits 12-lipoxygenase.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
